BPC-157 vs TB-500
BPC-157 and TB-500 are the two most frequently compared compounds in tissue-repair research. They are often discussed interchangeably, but the published preclinical literature describes two genuinely different biological routes. Understanding that difference is what determines which compound belongs in a given study design.
The short answer
BPC-157 is studied primarily as an angiogenic and growth-factor signaling compound — it is associated with new blood vessel formation and upregulated repair signaling at the site of injury. TB-500 is studied primarily as a cell-migration compound — through actin sequestration it is associated with the movement of repair cells into damaged tissue. One is about supplying and signaling; the other is about mobilizing.
Side-by-side comparison
| Attribute | BPC-157 | TB-500 |
|---|---|---|
| Origin | Synthetic 15-amino-acid sequence derived from a protein found in human gastric juice. | Synthetic fragment (roughly residues 17–23) of the 43-amino-acid protein Thymosin Beta-4. |
| Primary mechanism studied | Upregulation of growth factor expression (VEGF, EGR-1) and promotion of angiogenesis at injury sites. | G-actin sequestration, which supports cytoskeletal remodeling and cell migration into damaged tissue. |
| Tissue focus in literature | Tendon, ligament, muscle and gastrointestinal lining models. | Dermal wound, cardiac and broad soft-tissue migration models. |
| Systemic vs local behavior | Frequently studied for stability in gastric conditions; literature explores both local and systemic exposure. | Small fragment with rapid distribution; studied for systemic circulation to remote injury sites. |
| Typical research pairing | Often modelled alongside TB-500 because the pathways are complementary rather than overlapping. | Often modelled alongside BPC-157 for the same reason. |
| Handling | Lyophilized at -20°C; reconstituted with bacteriostatic water and refrigerated at 2–8°C. | Identical storage profile — lyophilized frozen, reconstituted refrigerated. |
BPC-157 in more detail
BPC-157 (Body Protection Compound-157) is a pentadecapeptide isolated from a protective protein sequence in gastric juice. Rodent studies have examined its association with tendon and ligament fibroblast outgrowth, gut lining integrity, and the expression of vascular endothelial growth factor. Because much of the published work involves the gastrointestinal tract, BPC-157 is frequently the reference compound in gut-barrier and systemic-stability models. Human clinical evidence remains limited.
TB-500 in more detail
TB-500 is a synthetic fragment of Thymosin Beta-4, an actin-binding protein present in nearly every mammalian cell type. Its most characterized property is the binding and sequestration of G-actin, which regulates the cytoskeletal rearrangement cells need in order to migrate. Preclinical wound-healing and cardiac models have explored this migration effect, along with downstream observations around inflammatory signaling.
Which one for which study?
- Vascularization, growth-factor expression, or gastrointestinal barrier endpoints point toward BPC-157.
- Cell migration, dermal wound closure, or cytoskeletal endpoints point toward TB-500.
Purity matters in comparison work
Any comparison between two compounds is only as reliable as the material behind it. Every Muscle Pump 26 lot ships with a third-party Certificate of Analysis documenting 99%+ purity, so results are attributable to the compound rather than to contaminants.
For research purposes only. Not for human consumption. Nothing on this page is medical advice or a therapeutic claim.